撰文丨王聪 编辑丨王多鱼 排版丨水成文 2025 年 10 月 7 日，克隆之父、诺贝尔生理学或医学奖得主、剑桥大学教授 约翰·格登 爵士 （ Sir John Gurdon ） 去世，享年 92 岁。 约翰·格登 是发育生物学领域先驱，他在 细胞核移植 方面的开创性研究解决了生物学中最基本的问题之一：遗传信息在发育过程中是得以保留还是丧失 。他的研 究工作为生物医学领域的重大突破铺平了道路——从干细胞生物学、小鼠遗传学到克隆技术和体外受精技术皆是如此。他发现了发育成熟的成年细胞可以被重编 程至胚胎干细胞状态 （即 多能干细胞 ） ，这一发现使他与 山中伸弥 共同获得了 2012 年诺贝尔生理学或医学奖。 约翰·格登 ，1933 年 10 月 2 日出生于英国汉 普郡 Dippenhall 。他曾就读于伊顿公学，但当时的成绩并不出色，尤其是生物学成绩垫底，他的一位老师曾写报 告称他立志投身科学的想法很荒唐。但格登依然坚持自己的梦想，并于 1957 年在牛津大学获得博士学位。在美国加州理工学院完成博士后研究后，格登于 1962 年回到英国。自 1971 年起加入剑桥大学。 我们的生命始于受精卵的分裂，形成新的细 ...

Core Viewpoint - The article discusses the innovative method of chemical reprogramming to generate human chemical induced pluripotent stem cells (hCiPS cells), highlighting its potential in regenerative medicine and the advantages of using human blood cells as a source for these stem cells [2][10]. Group 1: Chemical Reprogramming Method - The chemical reprogramming method allows for the conversion of somatic cells into pluripotent stem cells using a combination of small molecules, providing a more flexible and simpler approach compared to traditional transcription factor-based methods [2][6]. - In 2025, the team led by Professor Deng Hongkui successfully established an accelerated chemical reprogramming platform by overcoming key epigenetic barriers, enhancing the efficiency of generating hCiPS cells [2][4]. Group 2: Source of Cells - Human blood cells are identified as the most accessible and convenient source for generating hCiPS cells, although challenges remain in the chemical reprogramming of these cells [3][6]. - The research demonstrated high efficiency in chemical reprogramming from both fresh and frozen blood cells, with the ability to generate over 100 hCiPS cell clones from just a drop of fingertip blood [7][14]. Group 3: Research Highlights - The study published in Cell Stem Cell represents a significant advancement in the field, overcoming the critical bottleneck of starting cell sources for chemical induced pluripotent stem cell production [4][10]. - The method is noted for its robustness and reproducibility, making it a promising next-generation platform for efficient and scalable stem cell production in regenerative medicine [10][14].